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Abstract
Background Tenofovir (TDF) is considered as the first
line therapy for chronic hepatitis B. This study presents the
results of TDF monotherapy in patients who failed previous
nucleoside analogue treatment.
Methods The study included 29 patients treated with TDF
245 mg once daily for 18 months after lamivudine
monotherapy (LAM arm: n = 15) or sequential therapy
with lamivudine and entecavir (LAM ? ETV arm:
n = 14). The previous antiviral therapy was discontinued
due to lack of efficacy. All patients had HBV DNA
between 2.1 and 8.23 log10 IU/ml and 15 were HBeAg-
positive, while 45 % of patients had increased ALT
activity. Undetectable HBV DNA (\20 IU/ml) at months
3, 6, 12 and 18 was the primary endpoint in the study,
while HBeAg/HBsAg loss/seroconversion and ALT nor-
malisation were secondary endpoints.
Results Primary nonresponse to TDF was not observed.
HBV DNA was undetectable in 80, 80, 80 and 93 % in
LAM arm and 50, 71, 86 and 86 % in LAM ? ETV arm
patients, at 3, 6, 12 and 18 months of TDF therapy,
respectively. One patient achieved anti-HBeAg serocon-
version. 86.5 % of patients had normal ALT activity at the
end of the study. The baseline HBV DNA load, HBeAg
status and the length of the duration of TDF therapy
appeared significantly associated with the response to the
therapy. HBV DNA clearance occurred faster in HBeAg-
negative patients than in those positive for HBeAg.
Conclusions TDF is an effective antiviral medication in
patients with previous exposure to LAM or LAM and ETV.
Final proportion of patients who achieved unde-
tectable HBV DNA and had normal ALT activity in both
arms, was similar.
Keywords Antiviral therapy  Chronic hepatitis B 
Entecavir resistance  Lamivudine resistance  Tenofovir
disoproxil fumarate
Introduction
Hepatitis B virus (HBV) infection is considered a major
health care problem because occult hepatitis can lead to
liver fibrosis and subsequent cirrhosis resulting in end stage
liver disease. It has been documented that HBV infection is
a risk factor for the development of hepatocellular carci-
noma [1]. For these reasons, many antiviral therapies have
been developed to stop viral replication. Interferon was the
first treatment with proven efficacy against HBV. The next
lines of therapy were nucleos(t)ide analogues: lamivudine
(LAM), adefovir, telbivudine, entecavir (ETV) and
recently tenofovir (TDF). A new antiviral medication is
being introduced into clinical studies and marketed every
few years.
TDF is currently considered as the first-line therapy in
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antigen (HBeAg) status. It is recommended for the treat-
ment of naı¨ve patients but it can also be used in patients
who remained HBV DNA-positive after previous antiviral
therapies [1]. The number of patients who did not respond
to antiviral nucleos(t)ide therapy is growing around the
world. It is very important to resolve this problem. The aim
of our study is to present the results of TDF monotherapy




This is a retrospective review of 29 patients (21 males; 8
females) with confirmed HBV infection, without any other
liver disease (HCV infection, Wilson disease, alcoholic
liver disease, autoimmune liver disease) or HIV infection.
Fifteen patients received LAM monotherapy [100 mg
orally, once daily for 7–83 months (mean 38)] (LAM arm)
and 14 patients received sequential therapy with LAM
[100 mg/day for 6–29 months (mean 16)] followed by
ETV [1 mg orally, once daily for 8–70 months (mean 32)]
(LAM ? ETV arm). During the therapy, patients were
monitored by a reverse hybridization method using a Line
Probe Assay INNO-LIPA HBV DR V2, DR V2/3 from
Immunogenetics (Ghent, Belgium) for the presence of
HBV mutations indicating resistance to LAM (rLAM:
rtM204V/I, rtL180M, rtV173L) or ETV (rETV: rtT184G,
rtS202I/G) (Table 1). When suboptimal viral response or
rLAM occurred, LAM was switched to ETV or discon-
tinued. ETV was stopped when suboptimal viral response
was observed or rETV was detected.
Between July 2012 and March 2013, patients who failed
previous antiviral therapy by achieving only partial viro-
logic response (PVR), defined as a decrease in HBV DNA
of more than 1 log10 IU/ml but with HBV DNA measured
by real-time PCR assay still detectable after 12 months of
therapy, or who developed mutations, were switched
directly from their preceding therapies to tenofovir diso-
proxil fumarate (Viread; Gilead Sciences, USA) therapy
(245 mg orally, once daily for 18 months). The polymerase
sequence mutations using INNO-LIPA HBV DR V2/3
assay were also checked during TDF treatment at month 3,
6, 12 and 18. However, they could be detected only when
HBV DNA concentration was higher than 2.7 log10 IU/ml
([500 IU/ml).
All patients had liver biopsy assessed according to
Scheuer classification [2]. Liver biopsy was performed
within 2 years before the start of tenofovir therapy. Mild
fibrosis (S1–S2) was present in 20 subjects, and 8/9
patients with advanced fibrosis (S3–S4) had compensated
liver cirrhosis.
Methods
All treatments (LAM, ETV, TDF) administered to patients
described in this report and monitoring of treatment effi-
cacy were standard of care procedures performed accord-
ing to product characteristics, scientific guidelines [1, 3]
and local legal regulations.
Patients had a physical examination and laboratory
testing at baseline and after 3, 6, 12 and 18 months of TDF
treatment. The primary endpoint of the study was unde-
tectable HBV DNA (\20 IU/ml) at month 3, 6, 12 and 18
of treatment. HBeAg/HBsAg (hepatitis B surface antigen)
loss/seroconversion and alanine aminotransferase (ALT)
normalisation were secondary endpoints.
HBV DNA was quantified by PCR-based method, with
product analysis using real-time PCR, automatic DNA
isolation on the Cobas AmpliPrep apparatus and amplifi-
cation on a Cobas TaqMan Roche analyser (Amplicor HBV
monitor; Roche Diagnostics, Basel, Switzerland). The
lower limit of quantification was 20 IU/ml and it was linear
over the range from 20 to 1.7 9 108 IU/ml (1.3–8.23
log10).
HBsAg, HBeAg and HBeAb (hepatitis B e antibody)
were determined by chemiluminescent immunoassays
(CLIA), using a test from Biomedica (Vienna, Austria) and
the LIAISON XL analyser from DiaSorin (Saluggia, Italy).
ALT activity was measured using the ICFF method,
without pyridoxal phosphate at the temperature of 37 C,
using a test kit from Roche and Cobas Integra analyser
(Roche Diagnostics). ALT level B33 U/l and B41 U/l was
considered as normal for female and male, respectively.
Patients were not exposed to any additional activities or
study-related risk or procedures. The epidemiological case
report review was used to collect the data described in this
report and patients’ identities were not disclosed at any
point in this report; thus, there was no need to obtain Ethics
Committee approval for this study.







M204V ? L180M 8 6
M204V/I ? L180M ? V173L 1 3
M204V/I ? L180M ± T184G
± S202I/G
0 4
Lack of detected mutations 2 0
LAM lamivudine, ETV entecavir
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Statistical analysis
The results of TDF monotherapy assessed as unde-
tectable versus detectable HBV DNA level and normal
versus increased ALT activity in subsequent months of
therapy have been analysed using the generalized esti-
mating equations (GEE) for binary data, which takes an
account of the correlation between repeated observations
from the same individual at multiple time points. The
statistics for continuous variables are presented as median
with range and the categorical variables are presented as
frequencies. Differences between continuous variables
were analysed by Wilcoxon test and differences for cate-
gorical variables were tested using the v2 or Fisher exact
test for independence.
The results were considered statistically significant,
when the p value was\0.05. The statistical analysis was
performed with the use of the R software, v.3.0.3.
Results
Baseline patient characteristics
At the beginning of TDF therapy, the patients’ median age
was 41 years (20–81) and the median duration of HBV
infection was 14 years (1–33). The median viral load was
3.68 log10 IU/ml (2.1–8.23 log10). Fifteen patients were
positive for HBeAg. HBeAg was detectable in 4 patients
from the LAM arm and in 11 from the LAM ? ETV arm.
Median ALT activity in the study group was 28 U/l
(12–500). Thirteen patients (45 %) had increased ALT
activity (6 in the LAM arm, 7 in the LAM ? ETV arm).
Except for HBeAg distribution, there were no statistically
significant differences between patients from the LAM and
LAM ? ETV groups at the beginning of TDF treatment
(Table 2).
Virologic response
At month 18 of the study, 26 (90 %) patients achieved
complete virologic response (CVR), defined as unde-
tectable HBV DNA (\20 IU/ml), measured by real-time
PCR assay after 12 months of therapy [1]. The proportion
of patients with undetectable HBV DNA in the LAM arm
(93 %) did not differ significantly from the fraction of
patients in the LAM ? ETV arm (86 %) (Fig. 1, left
diagram).
In the LAM arm, the proportion of patients with unde-
tectable HBV DNA was 80 % at months 3, 6 and 12, and
increased to 93 % at month 18 (Fig. 1, left). In the LAM
arm, one patient had only partial virologic response at
month 18; however, the viral load was near the lower limit
of detection and registered as 1.47 log10 (30 IU/ml).
In the LAM ? ETV arm, the proportion of patients
with undetectable HBV DNA at month 3 was 50 %, but
increased to 71 % at month 6 and 86 % at months 12 and
18 (Fig. 1, left). Partial virologic response was achieved in
14 % of patients at month 18 of treatment. The mean HBV
DNA level was 1.75 log10 (57 IU/ml).
All patients had at least 1 log10 reduction in HBV DNA
concentration between baseline and 3 months of TDF
monotherapy. Primary nonresponse to TDF was not
observed. None of the patients developed virologic
breakthrough, defined as confirmed increase of HBV
DNA C 1 log10 IU/ml from nadir [1].
In order to study the dynamics of virologic response to
TDF therapy and the association of the response and fac-
tors which can increase or decrease the risk of insufficient
response to the therapy, a GEE model with logit link
function has been applied. The potential influence of
HBeAg status, baseline HBV DNA concentration, liver





LAM ? ETV arm
(n = 14)
Sex (male/female) 21/8 11/4 10/4
Age (years)
Min–max 20–81 21–78 21–81
Median 41 43 31
Duration of HBV infection (years)
Min–max 1–33 1–33 4–22
Median 14 16 12
HBV DNA (log10 IU/ml)
Min–max 2.1–8.23 2.1–8.23 2.21–7.48
Median 3.68 3.10 4.30
HBeAg status*
Positive 15 4 11
Negative 14 11 3
ALT (U/l)
Min–max 12–500 12–253 14–500
Median 28 25 33
Liver fibrosis (staging)
S1–S2 20 11 9
S3–S4 9 4 5
Activity of liver inflammation (grading)
G0–G2 20 11 9
G3–G4 9 4 5
LAM lamivudine, ETV entecavir, ALT alanine aminotransferase,
HBeAg hepatitis B e antigen, HBV DNA viral load
* v2: p = 0.01
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fibrosis, age and gender of the patients, length of the
duration of TDF monotherapy as well as the type of pre-
vious therapy (LAM vs. LAM ? ETV) and the presence
of polymerase sequence mutations on response has been
checked. However, for the examined group of patients,
HBeAg status, baseline HBV DNA concentration and the
length of the duration of TDF therapy appeared signifi-
cantly associated with the response to the therapy (Table 3,
Models 1 and 2), while other factors (liver fibrosis, age and
gender of the patients, the type of previous therapy and the
presence of polymerase sequence mutations) seem not to
exhibit a significant influence on the dynamic of virologic
response. A higher HBV DNA concentration at baseline
was observed, the lower being the probability of virologic
response to the therapy. The increase of HBV DNA con-
centration by 1 log10 at baseline decreases the odds of
virologic response versus no response by about 70 % on
average [OR = 0.29 (0.15 0.56); Table 3, Model 1] at any
time point. The length of duration of the TDF therapy
increases the probability of achieving undetectable HBV
DNA and the passage of each month increases the odds of
undetectable HBV DNA by about 20 % on average
[OR = 1.22 (1.00 1.48); Table 3, Model 1]. HBeAg status
at baseline also affected the virologic response and
HBeAg-positive status decreases the odds of the loss of
HBV DNA [OR = 0.25 (0.11 0.55); Table 3, Model 2;
Fig. 1, right].
Serologic response
HBsAg loss was not observed. All patients remained pos-
itive for HBsAg at the end of the study. HBeAg/anti-HBe
seroconversion occurred in one patient in the LAM arm at
month 18 of treatment.
Biochemical response
There were no statistically significant differences between
the proportion of patients with normal ALT activity at month
18 between the LAM arm (87 %) and LAM ? ETV arm
(86 %) (Fig. 2, left). At the end of the observation period,
ALT normalisation was observed in 86.5 % of patients.
In Fig. 2 (right), the proportion of patients with normal
ALT activity in HBeAg-positive and HBeAg-negative
groups is also shown. There was significant difference
between the proportion of patients with normal ALT
activity in HBeAg-negative and HBeAg-positive group at
baseline (11/14 vs. 5/15, p = 0.0381), but at month 3 and
subsequent months of the therapy, the difference was no
longer significant.
In order to investigate the dynamics of ALT activity in
subsequent months of therapy, a GEE model has been fitted
to the data (Table 3, Model 3). The potential influence of
HBeAg status, HBV DNA concentration, liver fibrosis, age
and gender of patients, the type of previous therapy (LAM
vs. LAM ? ETV) and the presence of the polymerase
sequence mutations on the increased ALT activity has been
evaluated. For this group of patients, HBV DNA concen-
tration (expressed as log10 HBV DNA) appeared to be the
only factor significantly associated with ALT activity sta-
tus. A higher HBV DNA concentration was observed, the
lower being the probability of normal ALT activity. The
increase of HBV DNA concentration by 1 log10 decreases
the odds of normal ALT activity by about 40 %
Fig. 1 Virologic response
during TDF treatment in LAM
arm versus LAM ? ETV arm
(left, p[ 0.05) and in HBeAg-
positive versus HBeAg-negative
patients (right, p = 0.0006)
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[OR = 0.59 (0.47 0.73)]. The other considered factors
seem not to show significant association with increased
ALT activity.
Polymerase sequence mutations during TDF
monotherapy
The presence of polymerase sequence mutations at baseline
did not influence virologic response during TDF
monotherapy. They were detectable until month 6 of the
treatment only in four patients (three in the LAM arm and
one in the LAM ? ETV arm) and remained the same at all
check points. Various combinations were observed; in the
LAM arm: M204V, M204V ? L180M and M204V ?
L180M ? V173L, each in one patient; in the LAM
? ETV arm: M204V ? L180M ? T184G ? S202G.
Discussion
The approach to the therapy of chronic hepatitis B has been
changing according to the availability of new antiviral
medications. Interferon was the first antiviral therapy used
in Poland, financed from public funds through the
Table 3 Results of the estimation of GEE models for virologic response i.e. undetectable versus detectable HBV DNA (Model 1 and Model 2)
and ALT activity i.e. normal versus increased ALT activity (Model 3)
Estimate Robust SE Z p value OR (CI)
GEE models for virologic response (undetectable vs. detectable HBV DNA concentration)
Model 1:
(Intercept) 5.890 1.578 3.733 0.0002
Time 0.196 0.100 1.961 0.0499 1.22 (1.00 1.48)
HBV DNA at baseline (log10) -1.250 0.344 -3.631 0.0003 0.29 (0.15 0.56)
Model 2:
(Intercept) -0.225 0.196 -1.151 0.2496
Time 0.264 0.076 3.476 0.0005 1.30 (1.12 1.51)
HBeAg-positive at baseline (Ref: HBeAg-negative) -1.396 0.405 -3.446 0.0006 0.25 (0.11 0.55)
GEE model for ALT activity (normal vs. increased ALT activity)
Model 3:
(Intercept) 2.341 0.587 3.991 \0.0001
Time -0.019 0.037 -0.507 0.6119 0.98 (0.91 1.05)
HBV DNA (log10) -0.528 0.111 -4.748 \0.0001 0.59 (0.47 0.73)
OR (CI) odds ratio with 95 % confidence interval, Robust SE robust standard error
Fig. 2 Patients with normal
ALT activity in LAM arm
versus LAM ? ETV arm (left,
p[ 0.05) and in HBeAg-
positive versus HBeAg-negative
patients (right, p = 0.0381 at
baseline)
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therapeutic anti-HBV programme [4]. Lamivudine was
introduced later as the first orally taken anti-HBV medi-
cation, and subsequently other medications became avail-
able [3, 5]. Patients participating in this study had a long
history of HBV infection. All subjects in the study had
received lamivudine, as for many years it was available as
the main antiviral medication in therapeutic programs
reimbursed by the Polish health care system.
Lamivudine seemed to have similar efficacy to inter-
feron but had none of the side effects reported with inter-
feron therapy. However, the efficacy of LAM was limited
by the emergence of HBV mutations that were resistant to
this therapy. LAM resistance increases progressively dur-
ing treatment at rates of 14–32 % annually, exceeding
70 % after 2 years of treatment [6]. For this reason,
patients receiving LAM are tested for HBV DNA load and
for the presence of these mutations. Lamivudine should be
discontinued or the patient switched to other antiviral
treatment if HBV DNA remains unchanged or a mutant
variant appears. In our study, the proportion of patients
positive for rLAM was greater than 75 % over the mean
treatment period of 38 months; thus, the recommended
approach to discontinue or switch the antiviral therapy was
justified.
Entecavir was introduced into Polish therapeutic pro-
grams for HBV patients a few years after lamivudine. It
could be used only in sequential therapy in patients who
failed LAM. ETV was well tolerated but the efficacy
profile was only slightly better than lamivudine and resis-
tance mutations could still occur. Due to its high frequency
of virologic breakthrough (43 % after 5 years of treat-
ment), the role of ETV salvage therapy in LAM-refractory
patients was limited [7]. The patients analysed in this study
were treated according to the Polish anti-HBV therapeutic
program regulations. All of them received LAM, then
stopped it and were switched to ETV when virologic
breakthrough or at least one resistance mutation was
detected. Sequential LAM and ETV therapy resulted in a
large number of patients with resistance mutations to these
medications.
It is well known that long-lasting HBV infection is a
slowly progressing process leading to severe liver disease.
For this reason, patients with HBV DNA replication are
considered candidates for antiviral therapy. The majority of
patients analysed in this study had mild liver disease with
normal or slightly abnormal ALT activity and mild liver
fibrosis. All of them remained highly positive for HBV
DNA and thus were at risk of liver disease progression; for
this reason, they were considered candidates for further
antiviral therapy.
TDF is a nucleotide analogue without cross-resistance
with nucleoside analogues like lamivudine, telbivudine and
entecavir. It is highly effective in the treatment of naı¨ve
patients. Multicentre randomised phase III studies have
shown that 7 years of the therapy resulted in unde-
tectable HBV DNA (\400 copies/ml) in 77 % of HBeAg-
negative and 60 % of HBeAg-positive patients. ALT nor-
malisation was achieved in 84 and 74 % of these patients,
respectively. Forty percent of subjects lost HBeAg [8].
Baran et al. [9] have reported the efficacy of TDF in 92
rLAM patients with high HBV DNA load (7.11 log10 IU/
ml). Twenty-one patients received TDF monotherapy,
while the remaining subjects were treated with a combi-
nation of LAM and TDF. At month 24 of therapy, a
complete virologic response (HBV DNA\ 20 IU/ml) was
noted in 89 and 88 % of these patients, respectively.
Similar results of TDF efficacy have been reported in the
ongoing long-term study (EudraCT no: GS-US-174-0121)
comparing TDF monotherapy with TDF and emtricitabine
combination in patients with rLAM. At week 96 of therapy,
HBV DNA was undetectable (\400 copies/ml) in 89 % of
rLAM patients who had baseline HBV DNA load greater
than 103 copies/ml [10]. Sangheun et al. [11] reported 70 %
rate of complete virological response (HBV
DNA\ 20 IU/ml) at month 12 of TDF monotherapy in
rLAM patients with a mean baseline HBV DNA load of 3.6
log10 IU/ml.
Our study confirms the above clinical observations on
the efficacy of TDF monotherapy in reducing HBV repli-
cation in patients who failed LAM treatment. Complete
virologic response at month 18 of therapy was achieved in
93 % of patients who failed previous antiviral therapy with
LAM and had a high viral load at the beginning of TDF
therapy. The majority of these patients were positive for
LAM resistance mutations.
Sequential LAM ? ETV treatment has been used in
some regions in the past; however, it has never been
widely recommended. Thus, the number of patients who
have received this type of therapy is small and the
number of reports on the efficacy of TDF therapy fol-
lowing the sequential LAM ? ETV regimen is limited.
Van Bo¨mmel et al. [12] reported one case and Lee et al.
[13] three cases of patients treated with TDF after
sequential LAM ? ETV therapy. There are also reports
describing the efficacy of TDF in patients with a subop-
timal virologic response during 24 weeks of ETV therapy.
Pan et al. [14] described the elimination of HBV DNA
and ALT normalization in 100 % of patients resistant to
ETV after 30 weeks of TDF treatment. These authors
recommend an early switch to TDF, before virologic
breakthrough or the emergence of resistance mutations
occurs.
Nowadays, TDF is recommended in patients with multi-
drug resistance to LAM and ETV [15, 16], and it is esti-
mated that the proportion of patients with HBV DNA
clearance (HBV DNA\ 20 IU/ml) should reach around
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65 % after 12 months of therapy [17]. The results descri-
bed in this paper show that 86 % of patients reached the
goal of the therapy at month 12. A CVR rate of 86 % at
month 18 of TDF therapy is satisfactory and is not statis-
tically different from the response in patients treated with
LAM monotherapy.
Our results show high efficacy of TDF, regardless of
previous antiviral therapy with LAM or LAM ? ETV.
However, there are several limitations to the study: it is
retrospective, the number of patients is small, and the
duration of observation is short. Despite these limitations,
we confirmed the high efficacy of TDF monotherapy
especially in patients with previous ineffective sequential
LAM ? ETV therapy. Likewise, history of prior exposure
(LAM monotherapy vs. sequential LAM ? ETV therapy)
had no influence on treatment outcome with tenofovir.
On the other hand, the data collected in this study come
from everyday clinical practice. The patients had docu-
mented HBV replication for many years and TDF was the
first antiviral medication that changed their virologic sta-
tus. Thus, we think that TDF monotherapy may be effec-
tively used in patients who did not respond to previous
LAM or LAM ? ETV therapy. We demonstrated high
efficacy of TDF in reducing HBV DNA load, but only one
(7 %) patient was cleared of HBeAg. Our result is close to
the 11 % rate of HBeAg clearance observed in the ongoing
GS-US-174-0121 study [10], but much lower than that
reported by Baran et al. (32 %) [9]. The latter authors
reported that HBeAg clearance occurred after at least
15 months of TDF therapy. The patients described in our
paper were not treated for longer than 18 months, and the
age at which they became infected with HBV did not
predispose them to a higher rate of HBeAg seroconversion.
Finally, effective suppression of HBV DNA is usually
followed by a reduction of inflammatory activity and nor-
malisation of ALT. This has been observed in all reports
[8–11, 17]. Our data show a marked increase in the per-
centage of patients with normal ALT activity in both
groups of patients treated with TDF.
Conclusion
TDF is an effective anti-HBV medication in patients with
previous exposure to LAM or LAM and ETV. Our study
showed that HBeAg status, baseline HBV DNA concen-
tration and duration of TDF therapy are significantly
associated with the response to therapy. TDF-induced HBV
DNA clearance occurred faster in HBeAg-negative patients
than in those positive for HBeAg. Furthermore, some
HBeAg-positive patients did not achieve unde-
tectable HBV DNA. Finally, the proportion of patients who
achieved the primary and secondary endpoints at 18 month
of therapy did not differ significantly in both arms.
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